Simcere Pharmaceutical Group Limited (2096.HK)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Jinsheng Ren | Co-Founder, Chairman & CEO | 7.91M | -- | 1962 |
| Mr. Yushan Wan | CFO, Joint Company Secretary & Executive Director | 7.45M | -- | 1970 |
| Mr. Renhong Tang Ph.D. | Executive Director | 9.71M | -- | 1981 |
| Ms. Xi Wang | VP & Executive Director | 1.89M | -- | 1983 |
| Mr. Shen Jun | CFO & Secretary of the Board of Simcere Zaiming | -- | -- | -- |
| Mr. Gaobo Zhou | Chief Investment Officer | -- | -- | 1979 |
| Mr. Quanfu Feng | Vice President of Marketing | -- | -- | 1965 |
| Dr. Tamas Oravecz Ph.D. | Senior VP & Chief Scientific Officer of Simcere Zaiming | -- | -- | -- |
| Dr. Aik Han Goh | Senior VP & Chief Medical Officer | -- | -- | 1975 |
| Mr. Wang John | Senior Vice President | -- | -- | 1961 |
Simcere Pharmaceutical Group Limited
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 6,584
Description
Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China. The company focusses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; COSELA, a trilaciclib hydrochloride for injection; Iremod, an iguratimod tablet; and XIANNUOXIN, a simnotrelvir tablets/ritonavir tablets. The company also offers promotion services for pharmaceutical products. In addition, it engages in the manufacture of pharmaceutical ingredients; and property management business. The company has a strategic regional licensing partnership with Vivoryon Therapeutics N.V. to develop and commercialize SIM0801 and other drugs in the Greater China region; and license and collaboration agreement with Guangzhou Fermion Technology Co., Ltd. to develop FZ002-037, an oral SSTR4 agonist for pain treatment. Simcere Pharmaceutical Group Limited was founded in 1995 and is headquartered in Nanjing, China.
Corporate Governance
Upcoming Events
March 24, 2025 at 1:06 PM UTC
Simcere Pharmaceutical Group Limited Earnings Date
June 18, 2025 at 12:00 AM UTC
Ex-Dividend Date
Recent Events
Recent Events Information Not Available